Farnesyltransferase inhibitors (FTIs) are anticancer compounds that inhibit Ras GTPases. Since Ras GTPases play key roles in T cell activation and function, we hypothesized that FTIs have immunomodulatory properties and are potential antirejection agents. An investigation was performed on a potent FTI to evaluate this hypothesis in the in vitro setting.
Introduction
The prototypic small GTPase Ras and its related small GTPase signal transduction proteins play pivotal roles in the regulation of cell activation and cell proliferation [1, 2] . A significant number of malignancies contain a mutation in Ras that leads to constitutive activation and subsequent unchecked cellular proliferation [3, 4] . Hence, Ras represents a logical target for the development of novel antineoplastic agents.
Ras and its related proteins are posttranslationally modified with hydrophobic isoprenyl groups (farnesyl-and geranylgeranylpyrophosphate) that allow their insertion into lipid membranes where they become activated and activate their effector signal transduction proteins [5] . Disrupting this posttranslational modification-farnesylation and geranylgeranylation-leads to the inability of these small GTPases to attach to the lipid membrane where they are activated. Farnesyltransferase inhibitors (FTIs) inhibit the enzyme farnesyltransferase that transfers farnesylpyrophosphate onto the carboxyl end of these signal transduction proteins, and thus this class of compounds represents promising antineoplastic agents [6] [7] [8] [9] . Several FTIs are currently being evaluated in clinical trials as anticancer agents and have been found to have less toxicity than conventional cytotoxic chemotherapeutic agents [10, 11] .
Success of organ transplantation depends, in part, on the suppression of donor reactive lymphocytes in the recipient. The cyclophilin inhibitors, cyclosporine (CsA) and FK 506, effectively suppress lymphocyte activation and currently represent the backbone of maintenance antirejection regimens in organ transplant recipients. However, current antirejection agents have significant side effects that lead to significant morbidity, infections, neoplasia and even mortality [12, 13] . Furthermore, these agents fail to prevent the development of chronic rejection, the major cause of long-term graft loss [12, 14] . These shortcomings provide the impetus for the discovery and development of novel immunomodulatory agents to be used in clinical organ transplantation.
T lymphocyte activation and effector functions are a requisite upon the proper function of Ras and its related proteins [15 -17] . It has been shown that Ras synergizes with calcineurin to activate the nuclear factor of activated T cells (NFAT) [18] . IL-2 production during T cell activation and signals from the IL-2, IL-3 and GM-CSF receptors are mediated by Ras [19, 20] . Inactivation of Ras has also been shown in T cell anergy [21] . Furthermore, Ras-related proteins such as Rac and Rho have been implicated in the formation of the immunological synapse between T lymphocyte and antigen presenting cell [22, 23] . Immunological synapse formation involves actindriven migration of membrane microdomains that contain coreceptors to the synapse between T cell and APC [24, 25] . In addition to Rac and Rho, Ras also affects actin polymerization and cellular morphology [26, 27] . FTIs have also been shown to cause morphological reversion in malignant cells by affecting the actin cytoskeleton [28] . The inhibition of Ras with FTIs may inhibit these early critical events of the T cell activation pathway. Hence, FTIs are not only potential anticancer agents but may also be clinically useful immunosuppressive agents. Here we investigated and defined the in vitro immunomodulatory properties of a potent FTI, A228839. We analyzed the effects of this potent FTI on T cell proliferation, T cell polarized shape, intracellular calcium kinetics, cytokine production and apoptosis.
Materials and methods

Lectin induced lymphocyte proliferation assay
Lymphocytes were isolated from the lymph nodes of euthanized Wistar rats (Charles River Laboratories, Wilmington, MA) under an approved institutional animal subject protocol. Briefly, lymph nodes were procured using sterile microdissection technique and placed in RPMI 1640 media (Life Technologies, Carlsbad, CA). Lymph nodes were teased apart and cellular material was passed through a 70-Am nylon mesh to remove debris. Lymphocytes were washed several times in PBS before resuspending in RPMI supplemented with 10% fetal bovine serum (FBS, Life Technologies), 2 mM L-glutamine (Sigma, St. Louis, MO), 100 U/ml penicillin (Life Technologies), 100 Ag/ ml streptomycin (Life Technologies), 1% nonessential amino acids (Sigma), 1 mM sodium pyruvate (Sigma) and 100 mM h-mercaptoethanol (Sigma).
Lymphocytes were then dispensed into the wells of a 96-well microtiter plate at a density of 1.5 Â 10 5 cells/well in a volume of 100 Al/well. A-228839 (Abbott Laboratories, Abbott Park, IL) and CsA (Novartis Pharma, Basel, Switzerland) were serially diluted from freshly made stock solutions and added to the wells. Treatments were performed in quadruplicate.
Phytohemagluttinin (PHA, Calbiochem-Novabiochem, San Diego, CA) was added to the wells to obtain a final concentration of 7 Ag/ml after a 12-h preincubation with drug. Lymphocytes were allowed to proliferate for 72 h and proliferation was then quantitated by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based CellTiter 96R AQ ueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI). A microplate reader (Bio-Rad Laboratories, Hercules, CA) was used to measure the absorbances of the wells at k = 490 nm. The measured absorbances of the wells which are related to the number of viable cells were averaged and the percent inhibition was calculated as: 100
, where exp, À cont and + cont denote experiment, negative and positive control, respectively. Percent inhibitions were determined for all concentrations tested in every experiment and then entered in a simple E max pharmacodynamic model to estimate the IC 50 using the software WinNonlin version 3.0 (Pharsight, Mountain View, CA).
Antigen presenting cell: antigen-induced lymphocyte proliferation assay
The murine hen egg lysozyme (HEL)-restricted CD4+ T cell (1E5) [29] and MHC II-restricted B cell (2PK3) hybridomas (a gift from M.D. Cahalan, UC Irvine) were maintained in RPMI 1640 supplemented with the above supplements. 2PK3 APCs were loaded with 100 Ag/ml HEL for 12 h. 1E5 T cells (0.5 Â 10 5 cells/well) and HEL-loaded, mitomycin C (Sigma)-treated 2PK3 cells (0.5 Â 10 5 /well) were placed in the wells of a 96-well microtiter plate in a volume of 200 Al/well. A-228839 was added in serial dilutions to the wells in quadruplicate immediately after or 1 h after the addition of 2PK3 cells. Proliferation was carried out for 48 h and was then quantitated by the MTS proliferation assay. The IC 50 was determined as described above for the lectin-induced proliferation assays.
T cell polarity
In physiological conditions the 1E5T cell has a characteristic polarized shape consisting of head and tail regions. Furthermore, it has been shown that intracellular calcium levels have been related to this polarized shape, and agents that abolish this polarized shape inhibit proper activation of these T cells [30] . To investigate the effects of A-228839 on T cell polarity, 1E5 T cells were dispensed into the wells of a 96-well plate at a density of 0.25 Â 10 5 cells/well and incubated with various concentrations of A-228839 for 8 h. Cells were then fixed in 1% formaldehyde in PBS solution. An inverted microscope was used to count the total number of cells and cells without polarized shape per high-power field. Cells were considered round if they were circular in shape and had no tail; elliptical-shaped cells and cells with identifiable head and tail regions were counted as polarized. Cells from three highpower fields per well were studied, and thus at each drug concentration approximately 400 to 500 cells from a total of nine high-power fields were counted. The average number of cells with polarized shape per high power field for each concentration was compared with untreated controls using the Student's t-test.
T cell [Ca 2+ ] i kinetics
Lymphocytes were isolated from rat lymph nodes as described above. Lymphocytes were incubated with various concentrations of A-228839 and/or CsA for 8 h prior to assays. The calcium indicator dyes fluo-4 and Fura-red (Molecular Probes, Eugene, OR) were added to cells in PBS at a concentration of 3 AM each. Lymphocytes were incubated with these calcium indicators for 1 h at room temperature protected from light. Cells were then washed three times in PBS and resuspended in RPMI and placed in growth conditions for 15 min.
One million cells of each sample were then analyzed by a FacsCalibur flow cytometer (BD Biosciences Immunocytometry Systems, San Jose, CA) and the mean FL-1 and FL-3 channels recorded every 10 s for a total of 220 s. At least 8000 events were acquired during each 10-s period. The FL-1 and FL-3 detector voltages were initially set so that their values were approximately equivalent on a resting control sample. This arbitrarily set the resting FL-1/FL-3 ratio to be approximately equal to 1, and these settings were not changed for the remainder of the experiment. PHA (20 Ag/ml) was added after the initial 30 s (resting period) to activate T cells. The [Ca ] i concentration is directly related to the ratio FL-1/FL-3. Data were analyzed using CELLQUEST software (BD Biosciences, Immunocytometry Systems).
PBMC cytokine production
Human PBMCs were isolated from fresh buffy coats obtained from the UCI Medical Center Blood Bank by Ficoll centrifugation under an approved institutional human subjects protocol. PBMCs (1 Â 10 6 cells/ml) in complete RPMI 1640 media were dispensed into 24-well plates (0.5 ml/well) and incubated with varying concentrations of A-228839 (0-2 AM, 1 well/concentration) for 30 min prior to addition of PHA (7.5 Ag/ml). Stimulated PBMCs were placed in growth conditions and supernatant fluids were collected 24 h later. Supernatant fluids were stored at À 80 jC until cytokine measurement.
Frozen supernatant fluids were thawed and centrifuged just prior to analysis. Cytokine measurement was performed with the Human Th1/Th2 Cytokine Cytometric Bead Array Kit (BD Biosciences Pharmigen, San Diego, CA) according to the manufacturer's directions. Cytokine-bound cytometric beads were analyzed on a FacsCalibur flow cytometer. Data output into listmode files was analyzed using the BD CBA Software (BD Biosciences Pharmigen). Cytokine concentration data were entered into an inhibitory effect pharmacodynamic model to estimate the IC 50 s for each cytokine using the software WinNonlin.
Apoptosis assay
Lymphocytes were treated with A-228839 8 h prior to simulation with PHA. After 24 h of activation, lymphocytes were incubated with FITC-conjugated annexin V (0.5 Ag/ml, BD Biosciences Clontech, Palo Alto, CA) for 15 min and then immediately analyzed on a FacsCalibur flow cytometer. Data were analyzed using CELLQUEST software (BD Biosciences, Immunocytometry Systems).
Results
A-228839 prevents lectin-induced lymphocyte proliferation
Lymphocytes were incubated with A-228839 for 12 h prior to addition of PHA and allowed to proliferate for 72 h. The FTI A-228839 was able to inhibit PHA-induced lymphocyte proliferation in a concentration-dependent manner. Fig. 1a is a representative MTS assay for A-228839. Addition of CsA (25 ng/ml) to varying concentrations of A-228839 results in increased inhibition of proliferation for this drug combination (Fig. 1a) . The IC 50 for A-228839 from three independent proliferation assays is 0.24 F 0.11 AM ( F S.E., Fig. 1b) . 
A-228839 prevents APC-induced T cell proliferation
Soluble mitogens such as PHA and anti-TCR antibodies activate T cells and stimulate proliferation; however, such activation does not approximate the in vivo activation by antigen and antigen presenting cells. To determine the effect of FTI on APC-induced T cell proliferation, murine 1E5 T cells were induced to proliferate with 2PK3 APCs loaded with HEL in the presence of varying concentrations of A-228839. A-228839 was able to inhibit APC-induced proliferation with an IC 50 = 0.10 F 0.09 AM when added 24 h prior to the addition of 2PK3 APCs (data not shown).
A-228839 disrupts 1E5 T cell polarized shape
To determine if farnesyltransferase inhibition affected T cell polarized shape, 1E5 T cells were treated with varying concentrations of A-228839 for 12 h and then inspected with light microscopy to assess cellular morphology. In Fig. 2a , untreated 1E5 T cells have a characteristic polarized shape containing head and tail regions while A-228839-treated cells have a round, nonpolarized appearance (Fig. 2b) . ] i after stimulation with PHA were about the same for untreated and treated lymphocytes, suggesting that farnesyltransferase inhibi- Human PBMCs in complete medium were treated with varying concentrations of A-228839 (0 -2 AM) 30 min prior to stimulation with PHA in a 24-well plate. Cytokine levels were measured in supernatant fluids (1 well/concentration) after a 24-h incubation with a cytometric bead analysis method. Experiments were repeated three times and IC 50 s were determined by inputting all data into an inhibitory effect pharmacodynamic model using WinNonlin software. 
A-228839 potently inhibits PBMC cytokine production
To determine if FTIs could inhibit lymphocyte cytokine production, we investigated the effects of A-228839 on lectin-activated PBMC cytokine production. A-228839 inhibited Th1 cytokine production in a concentration-dependent fashion with significant inhibition even at the lowest concentration tested (Table 1) . IL-2 and IFN-g production seemed the most sensitive to A-228839 treatment followed by TNF-a. A-228839 decreased PBMC production of the Th2 cytokines IL-4, IL-5 and IL-10 to a more variable degree (Table 1 ). (Fig. 4) . This shift to higher FL-1 signal values reflects a greater fraction of all lymphocytes undergoing apoptosis as compared to the stimulated control (83% vs. 31%).
A-228839 promotes apoptosis in lectin-activated lymphocytes
Discussion
In this study we have demonstrated the immunomodulatory properties of a potent FTI, A-228839. This agent is able to inhibit T cell activation signals by the CD2 (PHA induced activation and proliferation) pathway and seems to be more potent in inhibiting T cell activation by the CD3/CD4 (APC-induced activation and proliferation) pathway [30] . A possible explanation for this observation is that T cell activation by soluble mitogens such as PHA bypasses the immunological synapse formation. On the other hand, APC-induced proliferation requires immunological synapse formation, which we hypothesize to be inhibited by Ras inhibitors such as the FTI A-228839. We are currently performing live imaging cell studies to investigate the effects of FTI on immunological synapse formation.
Intracellular calcium increase is a very early event during T cell activation. Ineffective immunological synapse formation, such as that between APC and the tail region of the 1E5 T cell [31] ] i , which is suggestive of early apoptosis [34] . It may be that the [Ca 2 + ] i levels achieved in A-228839-treated lymphocytes after activation program these cells for an apoptotic in lieu of a proliferative fate. The results of our apoptosis studies agree with this hypothesis.
Another possible explanation for the increase in apoptosis in A-228839-treated lymphocytes is that signals from the IL-2 receptor that prevent apoptosis in T cells are mediated by Ras, and it has been shown that T cells transfected with a dominant negative Ras underwent apoptosis when stimulated with IL-2 [35] . Hence, Ras inhibition by A-228839 may prevent rescue signals from the IL-2 receptor in lymphocytes.
The effect of A-228839 on 1E5 T cell polarity indirectly supports our hypothesis that this agent disrupts the actin cytoskeleton. We have shown previously that perillyl alcohol, a geranylgeranyltransferase inhibitor, caused 1E5 T cells to lose their polarized shape and that these round cells failed to activate when placed in contact with an anti-CD3 antibodycoated bead [36] . This loss of polarized shape induced by perillyl alcohol was identical to the effects of cytochalasin D, an anti-actin agent, and dissimilar to the effects of colchicine, an antimicrotubule agent. We are currently investigating the direct effects of A-228839 on actin polymerization in T cells.
The combination of CsA and A-228839 resulted in an increased inhibition of PHA induced lymphocyte proliferation. Unexpectedly, the inhibition of proliferation by the combination of A-228839 and CsA appeared to be additive but not synergistic. It is not known why A-228839 does not synergize with CsA to inhibit T cell activation since it has been shown that Ras synergizes with calcineurin to regulate NFAT [18] .
Finally, as further proof that FTIs inhibit lymphocyte activation and function, we showed that A-228839 alone potently inhibited lectin-induced PBMC cytokine production. The differential inhibitory effects on PBMC cytokine production suggest that the small GTPases that A-228839 inhibits may play a more important role in signaling pathways controlling Th1 versus Th2 cytokine synthesis.
Transplantation allograft rejection and graft versus host disease is an immune process driven by alloreactive lymphocyte activation, proliferation and Th1 cytokine production [37] . Autoimmune-based rheumatologic, vasculitic, nephritic and gastrointestinal diseases also derive from unchecked lymphocyte activation, proliferation and cytokine production [38] . Our in vitro results with the FTI A-228839 suggest that farnesyltransferase inhibition may be a novel target for immunomodulation in these and other clinical settings. We are currently evaluating the efficacy of FTIs such as A-228839 in preventing allograft rejection and other immunological diseases in animal models.
In conclusion, we have shown that the FTI A-228839 potently inhibits lymphocyte activation and function. These immunomodulatory characteristics are distinct from those of CsA and require further investigation to delineate the mechanism of actions of this compound's various effects on lymphocytes. Our findings with A-228839 suggest that FTIs may represent a novel class of clinically relevant immunomodulatory agents.
